Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
May 24, 2013European Journal of EndocrinologyOpen Access

Mitotane levels predict the outcome of patients with adrenocortical carcinoma treated adjuvantly following radical resection

View Full Paper
Ask AI
Bookmark
Share

Why the study?

Does reaching and maintaining mitotane concentrations ≥ 14 mg/l improve recurrence-free survival in patients with radically resected adrenocortical carcinoma treated adjuvantly?

Population

122 patients with adrenocortical carcinoma who were radically resected between 1995 and 2009 and treated…

Comparison

Reaching and maintaining mitotane concentrations… vs Not reaching and maintaining mitotane…

Design

Cohort

Follow-up

median 36 months

Authors

MTMassimo TerzoloABAurélie BaudinAAArianna Ardito

Discussion

Loading...

Member takes

Overview

Supports target maintenance in adjuvant ACC; hypothesis-generating pending randomized confirmation.

Structured PICO

Does reaching and maintaining mitotane concentrations ≥ 14 mg/l improve recurrence-free survival in patients with radically resected adrenocortical carcinoma treated adjuvantly?

P
Population
122 patients with adrenocortical carcinoma (ACC) who were radically resected between 1995 and 2009 and treated adjuvantly with mitotane targeting concentrations of 14-20 mg/l
I
Intervention
Reaching and maintaining mitotane concentrations ≥ 14 mg/l
C
Comparator
Not reaching and maintaining mitotane concentrations ≥ 14 mg/l
O
Outcome
Recurrence-free survival (RFS)hard clinical

Maintaining mitotane concentrations ≥ 14 mg/l during adjuvant treatment of radically resected adrenocortical carcinoma is associated with prolonged recurrence-free survival.

Cite This Study

Terzolo et al. (2013) studied this question.

synapsesocial.com/papers/6a71fe5b6c240de38cdc47f3https://doi.org/10.1530/eje-13-0242
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1High-dose mitotane strategy in adrenocortical carcinoma: prospective analysis of plasma mitotane measurement during the first 3 months of follow-up2011 · 67 citations
  2. 2Improved Survival in Patients with Stage II Adrenocortical Carcinoma Followed Up Prospectively by Specialized Centers2010 · 158 citations
  3. 3Limited prognostic value of the 2004 International Union Against Cancer staging classification for adrenocortical carcinoma2008 · 694 citations
  4. 4The long-term survival in adrenocortical carcinoma with active surgical management and use of monitored mitotane2009 · 75 citations
  5. 5Adrenocortical carcinomas: surgical trends and results of a 253‐patient series from the French Association of Endocrine Surgeons study group2001 · 543 citations